inecalcitol
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02949570)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vitamin D receptorAGONIST
VDR agonist
orphan designation by EU January 2014
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C- Mol. weight
- 400.6 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105107 ↗
Also known as
- 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin d3
- 19-nor-14-epi-23-yne-1,25 dihydroxyvitamin d3
- 9,10-seco-14bh-19-norcholesta-5(z),7(e)-dien-1(r),3(r),25-triol-23-yne
- 9,10-seco-14bh-19-norcholesta-5(z),7(e)-dien-1(r),3(r),25-triol-23-yne
- inecalcitol
- inecalcitol
- inecalcitol
- inecalcitol
- inecalcitol
- tx 522
- tx-522
- tx-522
- tx-522
- tx 527
- tx-527
- tx527 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02802267 | Phase 2 | Jun 1, 2016 | Hybrigenics |
| NCT02949570 | Phase 2 | Feb 1, 2014 | Hybrigenics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hybrigenics | For profit | 2 | 2 | 1 | 2014 |
1 organizations
Page 1 / 1